奥美医疗(002950) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥820,581,799.40, representing a 37.32% increase compared to ¥597,558,015.66 in the same period last year[8] - The net profit attributable to shareholders for Q1 2021 was ¥116,304,971.88, up 27.53% from ¥91,195,258.97 in the previous year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥98,177,115.09, an increase of 11.45% compared to ¥88,093,169.40 in the same period last year[8] - The basic earnings per share for Q1 2021 were ¥0.1837, up 27.57% from ¥0.1440 in the same period last year[8] - The diluted earnings per share for Q1 2021 were also ¥0.1837, reflecting the same increase of 27.57% compared to ¥0.1440 in the previous year[8] - The company reported a net profit margin improvement, with net profit increasing due to higher revenues despite rising costs[40] Cash Flow - The net cash flow from operating activities for Q1 2021 was ¥13,427,440.70, a significant decrease of 96.18% from ¥351,379,371.51 in the previous year[8] - The cash flow from operating activities was CNY 624,769,899.08, down from CNY 810,309,454.99 in the previous year[48] - Operating cash inflow for Q1 2021 was CNY 737.77 million, a decrease from CNY 874.93 million in Q1 2020, resulting in a net cash flow from operating activities of CNY 13.43 million compared to CNY 351.38 million in the previous year[49] - The company's cash and cash equivalents decreased by CNY 259.49 million in Q1 2021, resulting in an ending balance of CNY 1,042.35 million compared to CNY 788.04 million at the end of Q1 2020[50] - The company reported a significant increase in cash received from other operating activities, amounting to CNY 912.32 million, compared to CNY 179.02 million in the previous year[52] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,299,173,298.76, reflecting a 9.12% increase from ¥4,856,080,464.92 at the end of the previous year[8] - The net assets attributable to shareholders at the end of the reporting period were ¥3,033,746,569.60, which is a 4.23% increase from ¥2,910,700,528.82 at the end of the previous year[8] - Total liabilities rose to CNY 2,252,623,591.18 from CNY 1,932,969,618.30, reflecting increased financial obligations[34] - The company's total assets as of March 31, 2021, amounted to CNY 4,116,504,849.34, an increase from CNY 3,787,115,816.84 at the end of 2020[36] Investments - The company made a long-term equity investment of CNY 543,487,043.10, a 38.07% increase, primarily in Sichuan Zhenghexiang Health Pharmacy Chain Co., Ltd.[15] - Long-term investments grew to CNY 1,437,340,027.95 from CNY 1,239,913,358.88, suggesting strategic investment in growth opportunities[36] Expenses - Research and development expenses surged by 218.02% to CNY 30,817,052.35, reflecting the company's commitment to enhancing R&D investment[16] - Financial expenses rose significantly by 400.32% to CNY 26,115,424.97, mainly due to increased foreign currency borrowings[15] - The gross profit margin was impacted by a 47.42% increase in operating costs, totaling CNY 566,067,253.13[15] - The company reported a 55.06% decrease in selling expenses, amounting to CNY 14,079,934.36, due to the reclassification of transportation costs under operating costs[15] Market and Risk Management - The company has engaged in trust financial products with an investment amount of CNY 40 million, with no overdue amounts reported[25] - The company has implemented measures to mitigate market risks, including foreign exchange derivatives to lock in exchange rates and reduce volatility risks[22] Other Information - The company reported non-recurring gains and losses totaling ¥18,127,856.79 for the reporting period[9] - The company reported no significant changes in accounting policies or estimates compared to the previous reporting period[24] - There were no violations regarding external guarantees or non-operating fund occupation by major shareholders during the reporting period[26] - The company has not undergone an audit for the Q1 2021 report, indicating that the figures presented are unaudited[55]